September 20, 2016
GSK today announced that Emma Walmsley, currently Chief Executive Officer of GSK’s Consumer Healthcare division, has been appointed GSK CEO Designate and will succeed Andrew Witty when he retires on March 31, 2017. Walmlsey will join the GSK Board of Directors from 1 January 2017. She has been a member of GSK’s Corporate Executive Team since 2011, joining the company in 2010 from L’Oreal where she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China. The appointment sees Walmsley, 47, become the seventh female chief executive in the FTSE 100, The Telegraph reported, and makes her "arguably the most powerful female boss in the index".
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.